Background: Remdesivir, a drug in use for Ebola it is already tested in clinical trials phase III.

Objective: To evaluate any other possible related structures with similar properties that could be used in clinical trials for COVID-19.

Methods: Molecular docking studies, DFT studies, ADMET studies.

Result: Saquinavir is a chemical structure with similar and even a better chemical activity that drugs that entered clinical trials for COVID-19.

Conclusion: Saquinavir should be entered the clinical trials for the treatment of the COVID-19 disease, as it has shown excellent binding affinities to SARS Cov-2 RNA depended polymerase and forms stable complexes with the protein and could possible inhibited its action.

背景：瑞德西韦是一种用于埃博拉病毒的药物，已在临床试验 III 期进行测试。

目标：评估可用于 COVID-19 临床试验的具有类似特性的任何其他可能的相关结构。

方法：分子对接研究、DFT 研究、ADMET 研究。

结果：沙奎那韦是一种化学结构，与进入 COVID-19 临床试验的药物具有相似甚至更好的化学活性。

结论：沙奎那韦应进入治疗 COVID-19 疾病的临床试验，因为它对 SARS Cov-2 RNA 依赖的聚合酶显示出优异的结合亲和力，并与蛋白质形成稳定的复合物，并可能抑制其作用。